跳至主要内容
临床试验/IRCT20140820018866N9
IRCT20140820018866N9招募中3 期

Evaluation of the Protective Effect of Metformin against the Tamoxifen Induced Changes on Endometrium and Ovaries in Women with Breast Cancer

Tehran University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
Female

入选标准

  • Adjutant treatment of breast cancer with tamoxifen
  • Normal pelvic exam
  • Performance state 0-2

排除标准

  • Serious diseases, heart or endocrine or other systemic diseases
  • Use of systemic hormone therapy during past 6 months
  • Alcohol consumption
  • Advanced breast cancer
  • Having any cancer or malignancy other than breast cancer during the last three years
  • Atypical hypoplasia or endometrial cancer
  • abnormal ovarian cysts with the possibility of malignancy on ultrasound
  • Contraindications for using metformin (eg: allergy to biguanides, acidosis, heart disease, alcohol consumption, gastroparesis, liver disease, hyperthyroidism or hypothyroidism, severe iron deficiency anemia, renal impairment)
  • Unbearable and dangerous side effects of metformin (such as: abdominal pain, chest pain, chills, cholestasis, severe diarrhea, dizziness, increased liver enzymes, severe headache, hepatitis, hypoglycemia, megaloblastic anemia, myalgia, palpitations, Skin rash and rash, vomiting)

研究者

相似试验